Authors of all three studies did not report adverse effects thus suggesting that targeting of endothelial cell markers such as angiomotin, TIE-2 and DLL-4, in anti-angiogenic design offers a safe and promising avenue for cancer vaccine therapy. This evidence concerns the gene AMOT and cancer.